Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.38 |
| ▸ | POU2F2 | P09086 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 10/20 | 0.35 |
| ▸ | CNR1 | P21554 | 9/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL262069 | 0.87 | MEN1 (0.59) | MEN1GAAKMT2AFOXO1POU2F2 | |
| SCHEMBL1242793 | 0.85 | MEN1 (0.52) | MEN1GAAKMT2AFOXO1CNR2 | |
| SCHEMBL4100133 | 0.81 | MEN1 (0.53) | MEN1GAAKMT2AFOXO1POU2F2 | |
| SCHEMBL4103702 | 0.81 | MEN1 (0.53) | MEN1GAAKMT2AFOXO1POU2F2 | |
| SCHEMBL4110428 | 0.81 | MEN1 (0.79) | MEN1GAAKMT2AFOXO1KDM4E | |
| SCHEMBL4099016 | 0.80 | MEN1 (0.51) | MEN1GAAKMT2AFOXO1POU2F2 | |
| Hydrochloric Acid SCHEMBL1243620 | 0.79 | MEN1 (0.66) | MEN1GAAKMT2AFOXO1CNR2 | |
| SCHEMBL4109622 | 0.79 | MEN1 (0.66) | MEN1GAAKMT2AFOXO1CNR2 | |
| SCHEMBL1244248 | 0.79 | MEN1 (0.56) | MEN1GAAKMT2AFOXO1CNR2 | |
| SCHEMBL4108658 | 0.79 | MEN1 (0.50) | MEN1GAAKMT2AFOXO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124617-A1 | QUINOLONE DERIVATIVE OR SALT THEREOF | THPO, ABL1, GMPS | MEN1 2643/4885GAA 1758/4885KMT2A 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.